Sanofi takes €100M charge after Dengvaxia analysis leads it to seek smaller label
admin 29th November 2017 Uncategorised 0After an analysis showed that Sanofi’s highly touted dengue vaccine could lead to more serious infections if used in the wrong setting, the company is requesting a label change that will likely lead to fewer eligible recipients. With the development, Sanofi is taking a €100 million ($119 million) charge in the fourth quarter.
More: Sanofi takes €100M charge after Dengvaxia analysis leads it to seek smaller label
Source: fierce